B-Body Pipeline
Oncology
Pre-clinicalActive
Key Facts
About Invenra
Founded in 2011, Invenra has developed a robust technology platform centered on its B-Body® bispecific antibody scaffold, which is engineered for high yield, stability, and simplified manufacturing. The company is advancing a pipeline of novel bi- and multi-specific candidates, initially focused on oncology, and has established strategic partnerships, such as with Twist Bioscience, to expand the reach of its platform. As a private company, Invenra combines internal R&D with a service-based business model, positioning itself as a key player in the next generation of antibody therapeutics.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |